Crinetics Gains Positive Analyst Rating as Palsonify, Atumelnant Advance

Key Facts

1Seeking Alpha issues a 'Buy' rating on Crinetics Pharmaceuticals following EU approval and strong initial US uptake of Palsonify for acromegaly.

2Q1 2026 Palsonify revenues reached $10.3 million, beating expectations.

3Crinetics advances atumelnant, an oral ACTH receptor antagonist, with promising Phase 2 data for CAH and Cushing's syndrome.

A new analyst endorsement highlights Crinetics Pharmaceuticals' progress in the endocrine drug space, as Seeking Alpha issues a 'Buy' rating following key pipeline milestones. The rating is driven by the EU approval and strong early US uptake of Palsonify for acromegaly, Q1 2026 revenues of $10.3 million that beat expectations, and promising Phase 2 data for atumelnant, an oral ACTH receptor antagonist for congenital adrenal hyperplasia (CAH) and Cushing's syndrome.

The positive analyst view underscores Crinetics' pipeline momentum, but the company faces a limited cash runway of approximately 12 months, making the commercial success of Palsonify critical for near-term financial stability. The broader biotech sector has seen mixed performance amid pricing pressures, though Crinetics' focus on niche endocrine therapies differentiates it from peers.

Looking ahead, investors will monitor Palsonify's revenue trajectory as it captures market share, as well as further clinical data for atumelnant. Additional catalysts include potential regulatory updates and the company's strategy to address its cash needs, possibly through partnerships or capital raises. The transition of Crinetics into a sustainable revenue-generating biotech will be a key focus for the market.